Zobrazeno 1 - 10
of 41
pro vyhledávání: '"John N. Feder"'
Autor:
Dike Qiu, Ke Xu, Namjin Chung, Jennifer Robbins, Robert Luo, Michael Lawrence, Aiqing He, Fei Yu, Andrew Alt, Michael M. Miller, Jon Hangeland, John N. Feder, Dietmar Seiffert, Brian J. Arey
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2023)
Vascular endothelial cells are exposed to mechanical forces due to their presence at the interface between the vessel wall and flowing blood. The patterns of these mechanical forces (laminar vs. turbulent) regulate endothelial cell function and play
Externí odkaz:
https://doaj.org/article/f3f3dd00eded4a689dfaf7ecdb19176f
Autor:
Q. Guo, G. Mintier, M. Ma-Edmonds, D. Storton, X. Wang, X. Xiao, B Kienzle, D. Zhao, John N. Feder
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
Abstract Using CRISPR/Cas9 delivered as a RNA modality in conjunction with a lipid specifically formulated for large RNA molecules, we demonstrate that homology directed repair (HDR) rates between 20–40% can be achieved in induced pluripotent stem
Externí odkaz:
https://doaj.org/article/7f2a87b2a216424889cfd9d640ef048d
Autor:
Stephen Hillerman, Andrew P. Degnan, Benjamin M. Johnson, Yi Fan, Elizabeth Duperret, Dandan Zhao, Jinqi Liu, John T. Hunt, John Morrison, Rajarshi Bhadra, Luisa Salter-Cid, Charu Chaudhry, Karen E. Parrish, Jennifer Koenitzer, Stephanie W. Briceno, Joshua Curtin, John N. Feder, Caitlyn Stromko, Emma Lees, Dan You, Anwar Murtaza, Michael Quigley, Gregory A. Locke, Mark D. Wittman, Giridharan Gokulrangan, Yali Chen, Chan Gao, Godwin Kwame Kumi, Miguel Sanjuan, Johnni Gullo-Brown
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundHematopoietic progenitor kinase 1 (HPK1 or MAP4K1) has been demonstrated as a negative intracellular immune checkpoint in mediating antitumor immunity in studies with HPK1 knockout and kinase dead mice. Pharmacological inhibition of HPK1 is
Autor:
John N. Feder, H. David Inzunza, Diana M. Cardona, John Cogswell, James Novotny, Gabe Mintier, Qiuyan Wu
Publikováno v:
Molecular Diagnosis & Therapy
Aim Nivolumab, a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has activity in melanoma, non–small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab is approved in
Autor:
D Storton, Gabe Mintier, Qi Guo, M Ma-Edmonds, Xuning Wang, D Zhao, John N. Feder, B Kienzle, X Xiao
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
Using CRISPR/Cas9 delivered as a RNA modality in conjunction with a lipid specifically formulated for large RNA molecules, we demonstrate that homology directed repair (HDR) rates between 20–40% can be achieved in induced pluripotent stem cells (iP
Autor:
Scott Priestley, Jeffrey Colin, Xuewen Ma, Michel Bouvier, Jacques Banville, Sophie Desmeules, Anne Marinier, Roger Remillard, Fraz A. Ismat, Mario Callejo, Ke Xu, Tao Wang, John N. Feder, Zhaoqing Wang, Gabe Mintier, Chi Sum, Jing Yang
Publikováno v:
Stroke. 47
Introduction: Protease-activated receptor 4 (PAR4) is a platelet thrombin receptor and a novel target for ischemic stroke treatment. Recent reports suggested a subtle racial difference in platelet responses to submaximal concentrations of PAR4 agonis
Autor:
Stefan Kirov, John N. Feder, Xuning Wang, Charles Tilford, Qi Guo, Isaac M. Neuhaus, Gabe Mintier
Publikováno v:
Bioinformatics. 33:3811-3812
Summary The simplicity and precision of CRISPR/Cas9 system has brought in a new era of gene editing. Screening for desired clones with CRISPR-mediated genomic edits in a large number of samples is made possible by next generation sequencing (NGS) due
Autor:
Howard Loraine, John N. Feder, Jean M. Whaley, Samantha Ho, Deborah Hagan, Jian Chen, Sandy Williams
Publikováno v:
Diabetes Therapy
SGLT2 (for “Sodium GLucose coTransporter” protein 2) is the major protein responsible for glucose reabsorption in the kidney and its inhibition has been the focus of drug discovery efforts to treat type 2 diabetes. In order to better clarify the
Autor:
Gabe Mintier, James K. Tamura, Ching-Hsuen Chu, Dong Cheng, Mark R. Harpel, Gregory A. Locke, Yuli Wu, Joseph W. Cook, John N. Feder, Luping Chen, Yongmi An
Publikováno v:
Protein Expression and Purification. 51:11-21
Acetyl coenzyme A (acetyl-CoA) carboxylase isozyme 1 (ACC1) and acetyl-CoA carboxylase isozyme 2 (ACC2) are critical for de novo fatty acid synthesis and for the regulation of beta-oxidation. Emerging evidence indicates that one or both isozymes migh
Autor:
John N. Feder, Dong Cheng, Rupalie Meegalla, Thomas C. Nelson, Jian Chen, Judith Wardwell-Swanson, Stephen G. Walker, Rebecca Taub, Jeffrey T. Billheimer, Michael Ramaker
Publikováno v:
Journal of Biological Chemistry. 278:13611-13614
Acyl coenzyme A:monoacylglycerol acyltransferase (MGAT) catalyzes the synthesis of diacylglycerol using 2-monoacylglycerol and fatty acyl coenzyme A. This enzymatic reaction is believed to be an essential and rate-limiting step for the absorption of